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Significance: Cutaneouswound regeneration is vital to keep skin functions and for
large wounds, to maintain human survival. In a deep burn, the ability of the skin
to heal is compromised due to the damage of vasculature and resident cells, hin-
dering a coordinated response in the regeneration process. Temporal skin substi-
tutes used as first cover can play a major role in skin regeneration as they allow a
rapid wound covering that, in turn, can significantly reduce infection risk, rate of
secondary corrective surgeries, and indirectly hospitalization time and costs.
Recent Advances: Skin was one of the first tissues to be bioengineered providing
thus a skin equivalent; however, what is the current status subsequent to 40
years of tissue engineering? We review the classic paradigms of biological skin
substitutes used as first cover and evaluate recent discoveries and clinical ap-
proaches adapted for burn injuries cover, with an emphasis on innovative cell-
based approaches.
Critical Issues: Cell-based first covers offer promising perspectives as they can
have an active function in wound healing, such as faster healingminimizing scar
formation and prepared wound bed for subsequent grafting. However, cell-based
therapies encounter some limitations due to regulatory hurdles, as they are
considered as ‘‘Advanced Therapy Medicinal Products,’’ which imposes the same
industry-destined good manufacturing practices as for pharmaceutical products
and biological drug development.
Future Directions: Further improvements in clinical outcome can be expected
principallywith the use of cell-based therapies; however, hospital exemptions are
necessary to assure accessibility to the patient and safety without hindering
advances in therapies.
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SCOPE AND SIGNIFICANCE
Temporal skin substitutes used
as first cover can play a major role in
skin regeneration, especially for deep
burns, as they allow a rapid wound
covering that, in turn, can signifi-
cantly improve subsequent clinical
outcomes. In this review, we discuss
the evolution of biological skin sub-
stitutes to include innovative cell-
based therapies, with associated
advantages and limitations.
TRANSLATIONAL RELEVANCE
In a deep burn, the ability of the
skin to heal is compromised due to
the damage of vasculature and resi-
dent cells, hindering a coordinated
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response in the healing process. The introduction of
next generation of biological skin substitutes could
stimulate regeneration by the release of a well-
proportioned combination of growth factors.
CLINICAL RELEVANCE
The care of large burn wounds is associated with
prolonged hospitalizations and significant costs
without mentioning the severe pain, emotional,
and physical strain that the burn trauma inflicts to
patients. Unmet needs still remain regarding suffi-
ciently advanced wound care therapies to improve
healing. Cell-based first covers offer innovative
approaches to treat burn wounds and cope with
the various burden.
BACKGROUND
The skin is the largest organ of the human
body, having the functions of controlling the body
temperature and peripheral fluid balance, allowing
sensation (e.g., heat, cold, touch, and pain) and pro-
viding a semipermeable protective layer against
pathogens.1,2 Although the skin has a spontaneous
self-regeneration ability, in some cases physiopath-
ological conditions hinder this ability: in chronic
wounds, such as in diabetic foot ulcer or pressure
ulcer, tissue homeostasis is disrupted because of an
altered paracrine signaling between keratinocytes
and fibroblasts3; in acute wounds (e.g., deep burns),
vasculature is damaged or partially damaged, thus
limiting the number of cells and factors brought for
regeneration.4 The time to wound closure is corre-
lated with higher risk of complications such as in-
fection, pain, and scarring occurrence.5
Several approaches have been developed over
the years to treat cutaneous wounds that have lost
their ability of spontaneous healing; split-thickness
skin autografting remains the gold standard treat-
ment for covering of large acute and chronic wounds
(Fig. 1).6 However, immediate wound covering by
surgery is not always possible such as in large
wounds of severely burned patients, as available
surface for donor skin is not sufficient for autograft-
ing. In such cases, alternative cell-based strategies
have been proven to be life saving, namely by the
cultured epithelial autografting (CEA), where the
patient’s own keratinocytes are expanded to form
stratified cell sheets that can be applied topically to
the patient for wound closure.7
In the mid-90s, we have also implemented at our
hospital a variant cell therapy, namely cultured
dermal–epidermal autograft (CDEA), which is based
on the same principle of stratified cell sheets as for
CEA, but allows to recreate a thicker skin graft,
because of a double layer composed of autologous
fibroblasts and keratinocytes.8 CDEA provides bet-
ter clinical outcome with a skin graft having more
functional mechanical properties than a CEA.
Nevertheless, CEA and CDEA techniques require a
minimum of 3 and 6 weeks, respectively, to expand
cells and build bioengineered thin skin grafts,
leaving the patient without cutaneous covering for
considerable time periods.
Temporary skin substitutes have a crucial
function in this specific case, as they are applied on
patients during the cell culture phase to prevent
fluid loss and decrease pain by nerve covering, but
most importantly provide a physical barrier that
can reduce infection risks.9 Indeed, wound infection
is thus the major cause of mortality, morbidity, and
wound healing delay.10,11 With >11 million people
affected annually by burn injuries worldwide,12
the prevalence of infection in burn units is*66%.13
Temporary skin substitutes may considerably re-
duce the costs and burden related to prolonged
hospitalization by reducing the risk of infection
and thus have amajor impact on the complications
requiring longer hospitalization periods.
In this study, we aim to present the different
types of temporary skin substitutes used as first
cover for skin burns, with a major emphasis on our
own experiencewith the history of the different first
covers used at the burn unit of our hospital, in-
cluding a comparison of the performance, costs, and
regulatory pathway of each temporary cover.
EVOLUTION OF TEMPORARY SKIN
SUBSTITUTES IN CLINICAL USE
Skin substitutes can be classified into two cate-
gories: permanent substitutes and temporary sub-
stitutes, which we name ‘‘first covers’’ (Fig. 2). Over
time, permanent skin substitutes have encompassed
all the cell-based grafting approaches, including
autografting of cultured and stratified cells with or
without the support of regenerative matrices. Tem-
porary skin substitutes have included xenogeneic
decellularized skin, allogenic cadaveric human skin,
actingmainly as a barrier to external contamination
andprotection of underlying tissue, but have evolved
to more sophisticated bioengineered formulations,
allowing rapidwould healing. In this section, wewill
present a brief overview of the different types of
temporary skin substitutes.
Conventional skin substitutes:
human cadaveric and xenogeneic
Several temporary skin substitutes were used
over time as first cover for partial- and full-thickness
burn wounds, for donor sites and meshed autograft
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protection. They have included human am-
nion (e.g., Mimedx or Osiris),14,15 xenografts16
(e.g., E-Z Derm, Mo¨lnlycke, Sweden), and hu-
man cadaver allografts, such as supplied by the
Euro Skin Bank (Beverwijk, Netherland). Por-
cine xenografts are probably the most frequently
used temporary skin replacement worldwide
due to easy accessibility and storage,17 but also
because porcine skin is anatomically close to hu-
man skin.18 Skin substitutes are available in several
forms: cryopreserved, in glycerol, lyophilized, and
decellularized.16,19–21 It has been reported that
storage in glycerol may be problematic as efficient
removal of glycerol residues from the xenograft
implies higher degradation rates of the substitute
on patients.22
Figure 1. Upper panel: Schematic illustration of split-thickness skin autografting and cell-based autografting; lower panel: Fabrication process of CEA and
CDEA. CDEA, cultured dermal–epidermal autograft; CEA, cultured epithelial autografting. Color images are available online.
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From our experience, cryopreserved allografts
give better protection than glycerol-preserved al-
lografts, probably because of a cryopreservation
allowing dermal substitutes to retain the ability to
release growth factors and biochemical cues pro-
moting wound healing.23 It has been shown that an
allogenic skin substitute becomes engrafted to the
wound after 2–3 weeks, thus the alloepidermis is
removed at surgery, leaving the dermal components
as a viable bed for a CEA.24 In some cases, remaining
allodermis parts even become re-epithelialized.25
The benefits of allografts and xenografts include
immediate soothing upon application, minimized
pain during dressing changes, and minimized pro-
tein and water loss, allowing the patient to resume
activity without disturbing the healing process.
However, theirmain drawbacks are the rejection-
related risks. Indeed, although the incorporated
dermis is usually not rejected in a first period, allo-
graft could trigger a chronic severe rejection reac-
tion when the patient’s immune system is restored.
This can also appear clinically with the formation
of unstable or hypertrophic scars.26 Furthermore,
these temporary substitutes may enhance risk of
disease transfer and their integration in the re-
cipient site renders their ablation difficult and
sometimes leaving painful eschars.8,27
Synthetic substitutes
Conventional skin substitutes are normally
overlayered by low-adherent sterile paraffin gauze
(Jelonet from Smith & Nephew Medical Ltd.,
England). On donor sites or when burn wounds
are smaller, gauze or foams only are applied
(synthetic dressings without allogenic/xenogeneic
substitute) as standard of care. Currently >3,000
types of dressings are available on the market,
offering a plethora of options to address all aspects
of wound care.28 In brief, these dressings encom-
pass materials made of semipermeable silicone
foams, hydrocolloids, hydrogels, and hydrofibers
as reviewed by Borda et al.29
Although these dressings mainly protect the
burn injury, they do not contribute to the recovery
of dermal and epidermal tissues. Synthetic sub-
stitutes can also be dermal constructs made of
nonbiological molecules and polymers not present
in normal skin. Although these substitutes offer a
stable and biodegradable environment for the re-
generation of tissuewith amore precisely controlled
composition and properties, the use of nonbiological
components can present biocompatible issues.30
Hence, there is still no superior synthetic sub-
stitute that can achieve complete healing, espe-
cially in case of chronic wounds such as venous leg
ulcers, diabetic wounds, and pressure ulcers.31
Nevertheless, synthetic dressings or substi-
tutes can be available in different formulations,
thus several dressings are often functionalized with
silver, iodine, or other antimicrobial agents to fur-
ther prevent infection.32–34 However, current anti-
microbials in use, most commonly silver, have the
limitation to induce skin irritation and staining af-
ter prolonged treatment.35
Bioengineered skin substitutes
Contemporary technological advances in bio-
materials have allowed to develop cell-based skin
substitutes, such asDermagraft or Transcyte from
organogenesis (Canton), which are made, respec-
tively, of polyglycolic acid/polylactic acid scaffolds
and collagen-coated nylon mesh, both seeded with
Figure 2. Skin substitutes classified into permanent and temporary substitutes. For both categories, products have evolved from conventional therapies to
bioengineered products combining various cells and biomaterials as strategies to improve wound healing. Color images are available online.
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allogeneic foreskin fibroblasts secreting growth
factors to aid wound healing.36
Other cell-free yet bioactive dressings have been
developed such as Biobrane (Smith & Nephew,
London, England), which consist of a semiperme-
able silicone film partially imbedded nylon, func-
tionalized with porcine collagen. Biobrane has the
benefit of minimizing bacteria proliferation on
wound surface by minimizing dead space, control-
ling water vapor loss (comparable with native skin),
and allowing conformability to surface irregulari-
ties. The latter property subsequently helps joint
movement and early ambulation due to its flexible
mechanical properties. A prospective randomized
clinical trial comparing both bioengineered prod-
ucts, Transcyte and Biobrane, indicated that the
cell-based Transcyte product promotes a faster
re-epithelialization, whereas requiring fewer
dressing changes and autografting procedures.37
Nevertheless, biocompatibility still remains the
major issue formost of the developed bioengineered
products, as they contain either allogeneic or xe-
nogeneic components with risks of inflammation or
rejection. To cope with this problem, we have de-
veloped at our hospital biological bandagesmade of
clinical-grade progenitor skin fibroblasts of fetal
origin, delivered to the burn wound on a collagen
matrix.38 These bandages positively impact wound
healing processes, most probably by secreting
growth factors, while inducing minimal inflam-
matory response due to their immune-privileged
source. Thus, we were able to show with eight
pediatric patients treated with biological bandages
alone that they did not require further associated
autologous grafting.38
Likewise, progenitor cells showed remarkable
outcomes in the treatment of donor site wounds
(Fig. 3) and chronic wounds with positive outcome.39
The progenitor cells are derived from a Federal
Transplantation Program following the Swiss con-
stitution for laws on research on human beings and
transplantation medicine (art 119a Cst). Fetal tissue
is considered as an organ donation from voluntary
pregnancy interruption and can be obtained with
specific strict regulation within transplantation law.
The benefits of bioactive substitutes may be
multiple depending on the severity of the burn
wounds. For superficial wound zones, they allow a
more rapid healing thus minimizing scar forma-
tion, whereas for intermediate zones, it can help to
reduce the edema and risks of thrombosis of the
capillaries; for deep wounds the bioactive compo-
nents prepare the wound bed, thus improving
subsequent grafting.
Alternative natural skin covers
Interestingly, skin substitutes derived directly
from nature have also been used as temporary
cover for burn patients, such as banana leaves,40
tilapia fish skin (e.g., Kerecis Omega3 fish skin) or
Figure 3. Use of biological bandages as cover for skin donor sites. (A) Back of pediatric patient with a deep burn at the right flank; (B) skin graft taken with
dermatome on healthy sites of the back; (C) application of the biological bandages on the donor sites of the back; (D) re-epithelization of the skin donor sites
after application of the biological bandages. Color images are available online.
FIRST COVERS FOR BURN WOUNDS 5
potato peel.22 Such approaches are often in use in
developing countries, where more sophisticated
and more expensive wound cover are not easily
available.
BENCHMARKING OF FIRST COVERS
In this section, we aim to give comparisons from
our own experience between the different types of
temporary substitutes used as first covers for
burn wounds, thus particular focus will be given
to cadaveric and porcine substitutes and the bi-
ological bandages, the three types of temporary
covers employed at the burn unit of our institu-
tion (Fig. 4).
From a purely practical point of view, the ad-
vantage of the biological bandages over the cadav-
eric and porcine substitute resides is the fact that
it can be easily removed from patients without be-
ing painful and leaving necrotic tissues (Fig. 5).
Biological bandages, on the contrary to the allo-
genic substitute, do not require staples to attach
to the patient, as they can be simply overlaid with
Jelonet followed by a Multivac compress, as a
standard of care.
Regarding the costs, the price of porcine cover
(E-ZDerm of 8·120 cm surface) is 321 Swiss Francs
(CHF), whereas a biological bandage (9·12cm)
costs 26 CHF. Consequently, to cover 1m2 of burn
surface would cost about 3,340 CHF for porcine
cover and 2,550 CHF for a biological bandage, which
is 25% less expensive. Themost expensivefirst cover
remains human cadaveric skin substitute as it costs
*12,000 CHF for the same surface of 1m2 (from
Skin Euro Bank, Netherlands).
If we put into perspective these numbers with the
costs of common dressings used in the standard of
care of burn wounds, such as Aquacel (ConvaTec,
United Kingdom) or a Jelonet paraffin Tulle Gras
dressing, for the same surface a cadaveric cover is
one order of magnitude more expensive than Aqua-
cel, and two orders of magnitude more than Jelonet.
Nevertheless, these numbers have to be normalized
over time as well, since a biological bandage or con-
ventional dressings can be changed several times
per week, whereas conventional covers can remain
several weeks without being changed.
The benefit of using such high-cost covers should
then be weighted by the impact they might have
on reducing hospitalization times, knowing that
patient care at the Lausanne University Hospital
(CHUV) Burn Unit costs 4,000 CHF per day. The
main advantage of biological bandages over allo-
genic and xenogeneic covers, respectively, remains
in the fact that it could actively stimulate wound
healing. Indeed, as already mentioned, a biological
bandagemay induce faster healingminimizing thus
scar formation, whereas for intermediate zones it
canhelp to reduce theedemaand risks of thrombosis
in capillaries, and for deep zones it can prepare the
wound bed thus improving subsequent grafting.
These advantages can positively impact wound
healing that, in turn, may reduce hospitalization
times and global costs, besides the fact that biological
Figure 4. Timeline of evolution of the first covers used at CHUV burn unit and the implementation of cell therapies. Color images are available online.
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bandages can readily be prepared within 24h from
an off-the-shelf goodmanufacturing practice (GMP)
cell bank, circumventing storage concerns.
Figure 6A shows the constant increase in the
number of biological bandages used at the Lau-
sanne University Hospital per year between 2013
and 2017, whereas the number of patients admit-
ted to the ICUburn unit per year remains constant,
which illustrated the implementation of biological
bandages in clinical routine in burn care, especially
for adult patients. This observation can also be il-
lustrated by the increase of mean number of ban-
dages used per patient over the years for a mean
total body surface area (TBSA) per patient that also
remains constant over time (Fig. 6B).
Interestingly, for the same year range, the indi-
cator of care duration normalized by burned surface
decreased from 0.6 days/TBSA in 2014 to 0.2 days/
TBSA in 2017 (for adults), thus suggesting an im-
provement in the quality of burn patient care, to
which the use of biological bandages may have
contributed, as all other aspects of burn care had
been standardized previously, except for small im-
provements in nutrition intake, which was adjusted
with supplement intake to cope with the exuda-
tive loss of trace elements within the first week.41
Figure 5. Photographs of a burn patient treated in a first time with E-Z Derm as first cover (left panel), and with biological bandages (right panel). Biological
bandages are applied the same day after E-Z Derm removal and debridement; they demonstrate superior outcomes in comparison with porcine substitute, as
shown by the lack of necrotic tissue, the absence of the staples and ease of handling. Color images are available online.
Figure 6. (A) Steady increase over time of production and use of biological bandages at the burn units of the Lausanne University Hospital, while number of
patients admitted to the burn center has remained constant. We can see that this increase of use of biological bandages is mainly due to the introduction of
this therapy as first cover for the adult patients. (B) Increase of the mean number of bandages used per patient, with a constant TBSA over time, which is
relevant to the fact that this therapy has been more used in clinical routine and not because of higher burn surface. TBSA, total body surface area.
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Table 1 summaries the assets that an ‘‘ideal’’ skin
cover could have.22,42
Finally, a consideration that might affect the
choice of a therapy or another is the use of certain
biological material that might be related to reli-
gious and/or ethical issues (for instance porcine
products for Muslim patients), which requires the
informed consent of the patient.
PERSPECTIVES ON FUTURE THERAPIES
Despite early excision, immediate wound cover-
ing, and topical treatments, the major problematic
remaining in burn patient care is the frequency
increase of persistent wound infections due to
hard-to-treat multidrug resistant bacteria, often
Pseudomonas aeruginosa.43 This is especially true
for large burn areas >40–50%. In an effort to cope
with burn wound infections, we are currently de-
veloping a next generation of biological bandages,
coupling antimicrobial dendrimers with progenitor
cells, thus allowing a dual effect of controlled in-
fection and enhanced wound healing.44
In the same perspective to improve wound heal-
ing, research endeavors aremade to genetically edit
keratinocytes to engineer skin equivalents, ex-
pressing factors that promote healing.16 Likewise,
studies have shown that mesenchymal stem cells45
and adipose-derived stem cells46 can promote
wound healing both by direct transfer onto wounds
by delivery embedded in scaffolds, as these cells can
secrete factors that attenuate inflammation and
stimulate angiogenesis, thereby leading to faster
wound closure.47
Although cell-based approaches show significant
performance in wound healing, offering promising
perspectives, they encounter some limitations due
to regulatory hurdles. Indeed, since 2007 new EU
regulations consider the application and practice of
cell therapies such as ‘‘Advanced Therapy Medicinal
Products’’ (ATMPs), imposing to cell therapies the
same industry-destined GMPs as for pharmaceutical
products. The aim of these regulations is to ensure
the safety of these products to a maximum extent.
However, these regulations imply considerable de-
lays in research, development, and the production of
cell therapies, which would not be of benefit to the
patients, without mentioning the increase in costs.
We advocate for ‘‘Hospital Exemption,’’ which
would provide a more suitable pathway to cus-
tomize safe product/therapy for access to industri-
alized patient care for burn victims.48 In this
respect, revisions on the Therapeutic Products Act
(Stage 2) have come into force, from January 2019,
in Switzerland. These revisions would simplify and
facilitate access to medicinal products for patients
and improve conditions for biomedical research. In
particular, it will entail a 2-year authorization for
the ‘‘compassionate use’’ of a cell-based therapy
provided that a clinical study has been approved in
Switzerland before the use request.
Other European countries, for instance Bel-
gium, have also applied the same kind of directives
for the compassionate use, especially for unproven
interventions such as the use of bacteriophages in
the treatment of persistent recalcitrant infections,
based on article 37 of the Declaration of Helsinki,
which stipulates.
‘‘In the treatment of an individual patient, where
proven interventions do not exist or other known
interventions have been ineffective, the physician,
after seeking expert advice, with informed consent
from the patient or a legally authorized representa-
tive, may use an unproven intervention if in the
physician’s judgement it offers hope of saving life, re-
establishing health or alleviating suffering. This
intervention should subsequently bemade the object
of research, designed to evaluate its safety and effi-
cacy. In all cases, new information must be recorded
and, where appropriate, made publicly available.’’
Therefore, we are now seeing that our policy-
makers are working hand-in-hand with those con-
fronted to help patients in the bestmanner possible.
CONCLUSIONS
In conclusion, temporary dermal substitutes
used as first cover for burn wounds can play a
major role in skin regeneration as they allow a
rapid covering of the wound and thus can signif-
icantly reduce infection risk by providing a
physical barrier to pathogens, but they can also
have an effect on the surface to be grafted and the
Table 1. Benchmarking of the biological bandages
and conventional allografts used as first covers
Property
Biological
bandage
(CHUV therapy)
Porcine
(E-Z Derm)
Cadaveric
(Euro Skin Bank)
Resist infection +/- + +
High absorbency potential ++ - -
Able to prevent water loss + + +
Nonadhesive to ease removal
(produce less pain)
++ - +
Withstand shear forces + + +
Cost-effective +/- - -
Widely available + ++ ++
Long shelf life ++ + +
Lack of antigenicity ++ - -
Conform to irregular
wound surfaces
+ + +
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rate of secondary corrective surgeries;
therefore, first covers can indirectly re-
duce hospitalization time and global costs.
Patient informed consent is also an
important matter to take into consider-
ation as the use of various biological prod-
ucts might incite religious and/or ethical
issues, which have not been notably docu-
mented in the medical literature for skin
substitutes.
Advances have been made in the de-
velopment of dermal substitutes in the
past years, and further improvements
in clinical outcome can be expected prin-
cipally with the approach of cell-based
therapies; however, hospital exemptions are nec-
essary to assure safety for patients without hin-
dering advances in therapies.
SUMMARY
First covers can improve clinical outcomes
in skin regeneration, by allowing a rapid wound
covering which subsequently can reduce infection
risk, rate of secondary corrective surgeries, and
thus hospitalization time and global costs. Recent
advances have shown significant improvement of
cell-based first cover for burn patients, thus offering
promising perspectives in wound healing; never-
theless, cell-based approaches encounter some
limitations due to regulatory hurdles.
Further improvements in clinical outcome can be
expected; however, hospital exemptions are neces-
sary to assure safety for patients without hindering
advances in therapies.
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TAKE-HOME MESSAGES
 A first cover is a temporary skin substitute that is employed to cover
large wounds until autografting.
 Over time, first covers have evolved from porcine and human allografts to
encompass cell-based therapy approaches.
 Biological bandages used as cell-based first covers have shown prom-
ising results, as the release of growth factors and cytokines by human
progenitor cells helps to prepare the wound bed before grafting and
allows faster wound healing, improving thus outcomes.
 Regulatory hurdles may impede the use of cell-based approaches, ad-
vocating for ‘‘Hospital Exemption,’’ which would provide a more suitable
pathway to customize safe therapy for burn victims.
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